Pharmas NDA for APF530 in avoidance of CINV: FDA issues Complete Response Letter A.

A.P. Pharma believes this scholarly study ought to be of short duration in regular volunteers. THE BUSINESS plans to go over the design and timing of the scholarly research with the FDA.P. Pharma that the Company did not review ahead of issuing the Complete Response Letter. The ongoing company believes these amendments may address some of the presssing issues raised in the entire Response Letter. The FDA has indicated a.P. Pharma may incorporate applicable sections of these amendments by particular reference in its resubmission. The ongoing company will become contacting the FDA to request an End-of-Review conference to discuss the Total Response Letter. A.P. Pharma expeditiously is committed to resolving the remaining issues required for FDA approval; however, based on the anticipated time needed to prepare a resubmission, the Company does not anticipate the commercial launch of APF530 this year 2010.Air Methods’ Products Division is the first in the globe to design, engineer, manufacture, and certify a medical interior for the Bell 429 helicopter. ‘Air Methods’ Products Division is quite excited to introduce the Bell 429 medical interior into our extensive products of crisis medical interiors, and honored to collaborate with Mercy One as the release customer,’ stated Tom Curtis, Vice President, Products Division. ‘We drew on our robust in-house knowledge in designing, engineering, manufacturing, and certifying helicopter medical interior completions to create this medical interior possible.